Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | Director | June 03, 2026 | June 04, 2026 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | 10% owner | December 11, 2025 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,995,498 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Exercise / conversion · Acquired 89,312 · Balance 1,995,498 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-03 · Exercise / conversion · Disposed 89,312 · Balance 0 F1: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2: Each restricted stock unit represents a contingent right to receive one share of common stock. |
| Common StockSEC Table I · non-derivative | IndirectBy Avicenna Life Sci Master Fund LP and related parties | 1,538,462 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,538,462 |
| Common StockSEC Table I · non-derivative | IndirectBy Invus Public Equities, L.P. and related parties | 7,362,368 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,362,368 |
| Common StockSEC Table I · non-derivative | IndirectBy Invus US Partners, LLC and related parties | 5,451,204 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,451,204 |
| Common StockSEC Table I · non-derivative | IndirectBy Invus, L.P. and related parties | 35,402,689 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 35,402,689 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
Scholar Rock Holding Corp
Report date December 11, 2025 · Filed February 06, 2026
Jointly reported with Invus Global Management, LLC, Siren, L.L.C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,825,013 |
Reported balance
After 2025-12-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-11 · Other · Acquired 1,575,008 · Balance 10,825,013 F1: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.35 · Expires 2025-12-31 | Direct | 0 |
Reported balance
After 2025-12-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-11 · Other · Disposed 1,575,008 · Balance 0 F1: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane.
F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blue Buffalo Pet Products, Inc.
Report date April 24, 2018 · Filed April 24, 2018
Section 16 reporting ended · disclosed 2018-04-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-24 transaction · row 1
1 source rowRow 1 · 2018-04-24 · Disposition to issuer · Disposed 10,569 · Balance 0 F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").
F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.
CRESCENT BIOPHARMA, INC.
Report date August 07, 2024 · Filed August 09, 2024
Jointly reported with Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Siren, L.L.C., Invus Global Management, LLC
Section 16 reporting ended · disclosed 2024-08-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,317,565 |
Last balance in matching sequence
After 2024-08-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-08-07 · Sale · Disposed 61,488 · Balance 6,578,438 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Row 2 · 2024-08-08 · Sale · Disposed 260,873 · Balance 6,317,565 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.
F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
WW INTERNATIONAL, INC.
Report date May 09, 2023 · Filed May 11, 2023
Section 16 reporting ended · disclosed 2023-05-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,387 |
Reported balance
After 2023-05-09 transaction · row 1
1 source rowRow 1 · 2023-05-09 · Grant · Acquired 835 · Balance 134,387 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 8,869 | $2.46 | $21,817.74 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,244 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 100 | $2.46 | $245.50 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 29 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,375 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 3,800 | $2.45 | $9,310.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 28 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,275 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 100 | $2.45 | $244.50 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 27 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,475 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 29,880 | $2.44 | $72,907.20 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 26 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,375 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 1,700 | $2.44 | $4,139.50 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 25 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,495 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 18,051 | $2.43 | $43,863.93 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 24 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,795 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 900 | $2.43 | $2,182.50 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 23 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,744 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 15,582 | $2.42 | $37,708.44 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 22 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,844 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 200 | $2.42 | $483.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 21 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,262 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 24,772 | $2.41 | $59,700.52 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 20 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,062 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 34,087 | $2.40 | $81,808.80 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 19 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,290 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 152 | $2.40 | $364.65 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 18 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,203 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 1,200 | $2.40 | $2,874.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 17 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,051 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 21,652 | $2.39 | $51,748.28 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 16 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,851 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 28,225 | $2.38 | $67,175.50 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 15 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,199 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 400 | $2.38 | $950.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 14 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,974 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 5,494 | $2.37 | $13,020.78 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 13 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,574 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 2,068 | $2.36 | $4,880.48 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 12 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,080 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 200 | $2.36 | $471.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 11 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,012 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 1,700 | $2.35 | $3,995.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 10 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,812 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 1,101 | $2.34 | $2,576.34 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 9 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,112 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 1,300 | $2.33 | $3,029.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 8 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,011 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 2,309 | $2.32 | $5,356.88 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 7 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,711 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 500 | $2.31 | $1,155.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 6 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,402 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 800 | $2.30 | $1,840.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 5 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,902 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 300 | $2.29 | $687.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 4 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,102 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 300 | $2.28 | $684.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,802 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 400 | $2.27 | $908.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,502 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:33 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 200 | $2.25 | $450.00 |
DisclosureSEC source: 0001127602-19-028595 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,102 Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:12 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 989 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040207 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,415 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:04 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 3,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016493 · form4.xml · derivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,466 Underlying: Common Stock · 3,466 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:04 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 6,519 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001127602-19-016493 · form4.xml · derivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,519 Underlying: Common Stock · 6,519 shares Expires 2029-04-26 F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:31 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 942 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023138 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,426 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:10 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 453 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001887 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,484 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:06 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GiftCommon Stock | 43,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-060557 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,031 Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:11 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-053772 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,156 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:55 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-049235 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,894 Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:14 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 187 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-041578 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,894 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| April 27, 2018 Filed Apr 27, 2018 21:37 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 2,857 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001127602-18-015443 · form4.xml · derivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 Underlying: Common Stock · 2,857 shares Expires 2028-04-27 F1 · derivative.exercise_date: Option vests with respect to 1/12th of the shares subject to the option for each month of service following the date of grant. Read SEC document |
| April 27, 2018 Filed Apr 27, 2018 21:37 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantCommon Stock | 2,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-015443 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,902 Read SEC document |
| April 24, 2018 Filed Apr 24, 2018 20:51 UTC | Blue Buffalo Pet Products, Inc. BUFF · Entity 167336 | Disposition to issuerCommon Stock | 10,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-010662 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · price: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:26 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 295 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-023648 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,707 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:16 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 390 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001922 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,412 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:46 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-055898 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,022 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 20:04 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 569 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043971 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,587 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| April 28, 2017 Filed May 1, 2017 20:50 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 2,857 | $0.00 Strike: $15.61 | $0.00 |
DisclosureSEC source: 0001127602-17-016058 · form4.xml · derivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 Underlying: Common Stock · 2,857 shares Expires 2027-04-28 F1 · derivative.exercise_date: Option vests with respect to 1/12th of the shares subject to the option for each month of service following the date of grant. Read SEC document |
| April 28, 2017 Filed May 1, 2017 20:50 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantCommon Stock | 1,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016058 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,338 Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 20:09 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 1,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-025590 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,018 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:37 UTC | Blue Buffalo Pet Products, Inc. BUFF · Entity 167336 | GrantCommon Stock | 3,695 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-009265 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,569 F1 · kind: Represents a grant of restricted stock that is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.